News | February 17, 2022
Asahi Kasei to build new filter assembly plant in Japan
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
The entire integration and transition of the brands is expected to be completed by March 2022
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
Funding to grow the insurance and digital therapeutics vertical in India
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
Subscribe To Our Newsletter & Stay Updated
